Terveystalo cuts its 2026 profit outlook as weak healthcare demand persists, though the company continues to expand its footprint through the strategic acquisition of Hohde Group.
Terveystalo has lowered its full-year 2026 adjusted EBIT guidance to EUR 110-120 million, down from the previous range of EUR 120-140 million, citing weaker-than-expected demand in the third quarter. The company reports that low morbidity and corporate cost-saving measures have negatively impacted volumes, and it expects the challenging demand environment to persist through the fourth quarter.
The guidance was lowered due to weaker-than-expected demand in July–September and the expectation that the challenging market environment will continue through the fourth quarter.
The transaction is ongoing and expected to be completed by the time of the postponed Capital Markets Day in spring 2027.
The Silmäasema transaction is a key component of Terveystalo's ARC strategy, aimed at strengthening its position in the growing eye health market. The acquisition is expected to broaden Terveystalo's customer base and improve service accessibility, with the company postponing its Capital Markets Day to spring 2027 to provide a clearer view of the combined business's value creation potential.
It is a significant step in the ARC strategy, designed to strengthen Terveystalo's position in the eye health market and broaden its customer base.
Terveystalo has postponed its Capital Markets Day to spring 2027, at which point it expects to provide a clearer view of the combined business and long-term value creation.
The completed acquisition of Hohde Group doubled Terveystalo's oral health business and strengthened its nationwide clinic network.
Terveystalo Plc has downgraded its full-year 2026 adjusted EBIT guidance to a range of EUR 110-120 million, down from the previous EUR 156.3 million recorded in 2025. The company cited persistent weak demand across all customer segments and lower volumes as the primary drivers for the shortfall, noting that cost-adjustment measures were insufficient to offset the market downturn.
The company lowered its guidance due to weaker-than-expected demand for healthcare services across all customer segments and lower volumes, which were not fully offset by internal cost-adjustment measures.
The Silmäasema transaction, announced in June, is ongoing. Terveystalo has postponed its Capital Markets Day to spring 2027 to ensure investors have a clearer view of the combined business potential once the deal is finalized.